Literature DB >> 9484803

Genotyping human arylamine N-acetyltransferase type 1 (NAT1): the identification of two novel allelic variants.

M A Payton1, E Sim.   

Abstract

Human arylamine N-acetyltransferase (NAT) is known to exist as two isoenzymes, NAT1 and NAT2, with different though overlapping substrate specificities. NAT1 and NAT2 are polymorphic at both genetic and phenotypic levels with four distinct alleles described in Caucasians for NAT1. Though clear genotype/phenotype associations exist for NAT2, the same remains unclear for NAT1. Whole blood taken from 32 individuals were NAT1 genotyped and compared to previously obtained NAT1 activities using p-aminobenzoic acid as a substrate. The NAT1 alleles of one individual, who had low NAT1 activity, were sequenced and compared to the wild type allele NAT1*4. A novel, non-conservative, substitution was present in both alleles at nucleotide position 560 and results in the exchange of an arginine for a glutamine at amino acid position 187. A glutamine is found in NAT2 at amino acid position 187 and has been implicated in substrate binding. This report describes a simple and effective genotyping method which detects the four previously reported NAT1 polymorphisms, and the described novel low acetylating polymorphism, by either NAT1 allele specific-PCR amplification or restriction fragment length polymorphism analysis of PCR amplified products. We suggest that NAT1 genotype/phenotype correlations will become more clear as further allelic variants are determined.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9484803     DOI: 10.1016/s0006-2952(97)00478-4

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  15 in total

1.  Interaction of wild type, G68R and L125M isoforms of the arylamine-N-acetyltransferase from Mycobacterium tuberculosis with isoniazid: a computational study on a new possible mechanism of resistance.

Authors:  Ricardo Martins Ramos; Janaína Menezes Perez; Luis André Baptista; Hermes Luís Neubauer de Amorim
Journal:  J Mol Model       Date:  2012-03-30       Impact factor: 1.810

2.  Acetylation of arylamines by the placenta.

Authors:  V A Smelt; H J Mardon; C W Redman; E Sim
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1997 Oct-Dec       Impact factor: 2.441

3.  Carcinogen metabolism, cigarette smoking, and breast cancer risk: a Bayes model averaging approach.

Authors:  Nadine Stephenson; Lars Beckmann; Jenny Chang-Claude
Journal:  Epidemiol Perspect Innov       Date:  2010-11-16

4.  Performance of amplified DNA in an Illumina GoldenGate BeadArray assay.

Authors:  Julie M Cunningham; Thomas A Sellers; Joellen M Schildkraut; Zachary S Fredericksen; Robert A Vierkant; Linda E Kelemen; Madhura Gadre; Catherine M Phelan; Yifan Huang; Jeffrey G Meyer; V Shane Pankratz; Ellen L Goode
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-07       Impact factor: 4.254

5.  Modification by N-acetyltransferase 1 genotype on the association between dietary heterocyclic amines and colon cancer in a multiethnic study.

Authors:  Lesley M Butler; Robert C Millikan; Rashmi Sinha; Temitope O Keku; Scott Winkel; Brent Harlan; Allison Eaton; Marilie D Gammon; Robert S Sandler
Journal:  Mutat Res       Date:  2007-10-13       Impact factor: 2.433

Review 6.  N-acetyltransferase SNPs: emerging concepts serve as a paradigm for understanding complexities of personalized medicine.

Authors:  David W Hein
Journal:  Expert Opin Drug Metab Toxicol       Date:  2009-04       Impact factor: 4.481

Review 7.  Functional expression of human arylamine N-acetyltransferase NAT1*10 and NAT1*11 alleles: a mini review.

Authors:  David W Hein; Giannoulis Fakis; Sotiria Boukouvala
Journal:  Pharmacogenet Genomics       Date:  2018-10       Impact factor: 2.089

8.  Functional analysis of arylamine N-acetyltransferase 1 (NAT1) NAT1*10 haplotypes in a complete NATb mRNA construct.

Authors:  Lori M Millner; Mark A Doll; Marcus W Stepp; J Christopher States; David W Hein
Journal:  Carcinogenesis       Date:  2011-11-22       Impact factor: 4.944

9.  Polymorphisms in GSTT1, GSTM1, NAT1 and NAT2 genes and bladder cancer risk in men and women.

Authors:  Monica McGrath; Dominique Michaud; Immaculata De Vivo
Journal:  BMC Cancer       Date:  2006-10-06       Impact factor: 4.430

10.  NAT gene polymorphisms and susceptibility to Alzheimer's disease: identification of a novel NAT1 allelic variant.

Authors:  Nichola Johnson; Peter Bell; Vesna Jonovska; Marc Budge; Edith Sim
Journal:  BMC Med Genet       Date:  2004-03-17       Impact factor: 2.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.